Neurológia pre prax 6/2018
Teriflunomid u mladých žen
Teriflunomide is medicine used for treatment of relapsing- remitting multiple sclerosis. It is administered as oral tablet once daily. Its safety profile and effectiveness were verified in four clinical trials and is supported with 13 years of clinical experience. Medicine is well tolerated by patients, adverse effects are mostly mild to moderate. This article shows on important data for clinical practice especially focused on treatment of young women, that are necessary to consider before and during treatment with teriflunomide.
Keywords: multiple sclerosis, teriflunomide, young women, pregnancy, accelerated elimination












